Evidence map›Paper›PMID 22490510›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2012

Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.

Archana Raamanathan, Glennon W Simmons, Nicolaos Christodoulides, Pierre N Floriano, Wieslaw B Furmaga, Spencer W Redding, Karen H Lu, Robert C Bast, John T McDevitt

Abstract readEvaluation StudyValidation Study
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Different Approaches to Develop Nanosensors for Diagnosis of Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Archana RaamanathanDepartments of Bioengineering and Chemistry, Rice University, Houston, TX 77005, USA.
Glennon W Simmons
Nicolaos Christodoulides
Pierre N Floriano
Wieslaw B Furmaga
Spencer W Redding
Karen H Lu
Robert C Bast
John T McDevitt

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0M
Effects of Oral Inflammation on the Levels of Salivary Biomarkers of AMIU01DE017793 · NIDCR · UNIVERSITY OF TEXAS AT AUSTIN · PI MCDEVITT, JOHN T · 2006 to 2012
$13.0M
Saliva Analysis with an Array SensorU01DE015017 · NIDCR · UNIVERSITY OF TEXAS AUSTIN · PI ANSLYN, ERIC V · 2002 to 2005
$3.6M
Refining & Implementing Supramolecular Methods for HTS of EE & ConcentrationR01GM077437 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI ANSLYN, ERIC V. · 2006 to 2021
$3.4M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA 83639NIDCR NIH HHS U01 DE015017NIDCR NIH HHS U01 DE017793NIGMS NIH HHS R01 GM077437
6 · The paper itself

Abstract

Point-of-care (POC) implementation of early detection and screening methodologies for ovarian cancer may enable improved survival rates through early intervention. Current laboratory-confined immunoanalyzers have long turnaround times and are often incompatible with multiplexing and POC implementation. Rapid, sensitive, and multiplexable POC diagnostic platforms compatible with promising early detection approaches for ovarian cancer are needed. To this end, we report the adaptation of the programmable bio-nano-chip (p-BNC), an integrated, microfluidic, and modular (programmable) platform for CA125 serum quantitation, a biomarker prominently implicated in multimodal and multimarker screening approaches. In the p-BNCs, CA125 from diseased sera (Bio) is sequestered and assessed with a fluorescence-based sandwich immunoassay, completed in the nano-nets (Nano) of sensitized agarose microbeads localized in individually addressable wells (Chip), housed in a microfluidic module, capable of integrating multiple sample, reagent and biowaste processing, and handling steps. Antibody pairs that bind to distinct epitopes on CA125 were screened. To permit efficient biomarker sequestration in a three-dimensional microfluidic environment, the p-BNC operating variables (incubation times, flow rates, and reagent concentrations) were tuned to deliver optimal analytical performance under 45 minutes. With short analysis times, competitive analytical performance (inter- and intra-assay precision of 1.2% and 1.9% and limit of detection of 1.0 U/mL) was achieved on this minisensor ensemble. Furthermore, validation with sera of patients with ovarian cancer (n = 20) showed excellent correlation (R(2) = 0.97) with gold-standard ELISA. Building on the integration capabilities of novel microfluidic systems programmed for ovarian cancer, the rapid, precise, and sensitive miniaturized p-BNC system shows strong promise for ovarian cancer diagnostics.

Indexed as

Lab-On-A-Chip DevicesBlood Chemical AnalysisCA-125 AntigenCalibrationCarcinomaComputersEarly Detection of CancerEnzyme-Linked Immunosorbent AssayFemaleHumansMicrochip Analytical ProceduresModels, BiologicalOsmolar ConcentrationOvarian NeoplasmsPoint-of-Care SystemsCA-125 Antigen

Identifiers

PMID22490510
PMCPMC3677577

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.